Interview with Kelly G. Gwathmey, MD, author of Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD. Related Content: Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis Gefurulimab—The First Effective Nanobody in Myasthenia Gravis Therapy
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from JAMA Network
JAMA Internal Medicine : MUTTON -HF (Medically Utilized Tailored Traditional foods to Optimize Nutrition in Heart Failure):A Randomized Trial of an Indigenous Food is Medicine Intervention
JAMA Otolaryngology–Head & Neck Surgery : Uncoded Tracheostomy Care—Impacting Care, Quality, and Research?
JAMA Ophthalmology : Nicotinamide and Primary Open-Angle Glaucoma in Ocular Hypertension
JAMA Surgery : Whole-Blood Transfusion From Empiricism to Evidence
Get summaries like this every morning.
Free AI-powered recaps of JAMA Network and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.